FNIH and PathAI Forge Partnership to Advance Mucosal Healing in Ulcerative Colitis Research
PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, is pleased to announce that the Foundation for the National Institute of Health's (FNIH) Biomarkers Consortium - Mucosal Healing in Ulcerative Colitis project team has selected PathAI to be its technology partner to further the study of mucosal healing, bring AI-assisted precision to disease assessment, and drive cutting-edge research to facilitate the development of new therapies for ulcerative colitis (UC), a disease affecting 1 to 2 million in the US alone.1, 2
“Ulcerative colitis is an increasingly prevalent chronic disease. The lack of standardized measurement and definition of mucosal healing poses a significant challenge for UC drug development, limiting treatment options for patients,” said James O’Leary, Director, Inflammation and Immunity at the FNIH. Though nearly 200 active clinical trials support on-going development of new treatments and therapies,3 no standard histological measure exists. “Through this collaborative project with PathAI, together we aim to establish a reproducible methodology for histological measurement of mucosal healing in UC treatment.”
PathAI’s groundbreaking AI product, AIM-HI UC (AI-based Measurement of Histological Index for Ulcerative Colitis), will serve as the exclusive platform for automated Geboes-based disease assessment for the consortium. This innovative approach will provide invaluable insights into mucosal healing, enabling better capture of true drug effect/signal-to-noise ratio for UC treatments. Furthermore, this partnership holds the potential to fuel biomarker development by unraveling the inflammatory microenvironment of ulcerative colitis.
The FNIH Biomarkers Consortium brings together eight prominent biopharmaceutical companies, two prominent disease area foundations, academic partners, and the FDA in an unprecedented effort to standardize and enhance disease assessment in the field of ulcerative colitis. By selecting PathAI as its technology partner, the consortium aims to leverage PathAI’s expertise in AI algorithms to achieve a more accurate and reproducible scoring of mucosal healing and provide improved prediction of long-term patient outcomes. The project will culminate in a common protocol and white paper that will be submitted to the FDA to influence regulatory guidance for future UC clinical trials.
"PathAI's algorithms will elevate our ability to investigate novel relationships, signatures, and biomarkers in UC" said Andy Beck, CEO of PathAI. "By embracing an AI-driven standardized approach, we increase accuracy and reduce scoring variability for therapeutic response assessment. We are excited to be part of this groundbreaking project, with the ultimate goal of accurately predicting long-term patient outcomes and driving industry-wide consensus."
One distinguishing feature of AIM-HI UC is that it is built on exhaustive WSI tissue segmentation and cell classification models, providing a quantitative and objective basis for a normally subjective assessment. Compared to traditional pathologist scoring, AIM-HI UC has demonstrated higher accuracy in measuring critical Geboes metrics essential to histological healing, including GS2A, GS2B, and GS3.
AIM-HI UC is intended for research use only, not for use in diagnostic procedures, serving as a secondary and/or exploratory endpoint in clinical trials. It enables the identification of histologic remission (GS<2) and histologic improvement (GS≤3.1). Additionally, it facilitates translational research and retrospective deployment.
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases.
PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com.
The Foundation for the National Institute of Health (FNIH) is a non-profit organization that provides critical support to the National Institutes of Health (NIH). FNIH works to advance biomedical research by fostering public-private partnerships and collaborations that accelerate the development of new treatments and therapies.
SVM Public Relations and Marketing Communications
View source version on newsdirect.com: https://newsdirect.com/news/fnih-and-pathai-forge-partnership-to-advance-mucosal-healing-in-ulcerative-colitis-research-888525887